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Abstract
The identification of the cystic fibrosis (CF) gene opened the way for gene therapy. In the ten
years since then, proof of principle in vitro and then in animal models in vivo has been
followed by numerous clinical studies using both viral and non-viral vectors to transfer normal
copies of the gene to the lungs and noses of CF patients. A wealth of data have emerged
from these studies, reflecting enormous progress and also helping to focus and define key
difficulties that remain unresolved. Gene therapy for CF remains the most promising
possibility for curative rather than symptomatic therapy.
Keywords: cationic lipids, CFTR, cystic fibrosis, gene therapy, recombinant viruses
Received: 28 April 2000
Revisions requested: 25 May 2000
Revisions received: 1 September 2000
Accepted: 1 September 2000
Published: 15 September 2000
Respir Res 2000, 1:78–81
The electronic version of this article can be found online at
http://respiratory-research.com/content/1/2/078
© Current Science Ltd (Print ISSN 1465-9921; Online ISSN 1465-993X)
AAV = adeno-associated virus; CF = cystic fibrosis.
http://respiratory-research.com/content/1/2/078
The cloning of the CF gene with subsequent characterisa-
tion of its protein (CFTR) [1] opened the way for gene and
protein therapy. The idea was simply to administer the
normal CF gene or protein, as though it were a drug, to
the organ most affected yet apparently quite accessible:
the lungs. In theory this should result in the restoration of
normal cellular function and thus prevent or treat the
disease. A vigorous research effort followed the identifica-
tion of the gene; the first reports of CFTR gene transfer in
vitro appeared in 1990 [2], only one year later. Further
studies in vitro [3] were followed by gene transfer in vivo
to the airway epithelial cells of transgenic CF mice [4,5],
confirming that it was possible to achieve some functional
restoration of the ion transport defects in these cells after
transgene expression. Within four years, four clinical
studies of gene therapy in CF patients had been reported;
since then there have been over 20 phase I studies.
Several of these trials used adenoviral vectors to transfer
CFTR cDNA to adult volunteers with CF; many of these
trials have now been reported [6–13]. Some early studies
reported acute inflammation, which was probably related
to the local instillation of a high viral load. There has been
evidence of gene transfer as determined by the detection
of mRNA or CFTR protein, although this was not a con-
sistent finding. Electrophysiological correction has been
suggested in some studies, but only one study was con-
trolled and this showed limited evidence of gene transfer
at the highest dose, with no evidence of functional cor-
rection. Two clinical trials with adeno-associated virushttp://respiratory-research.com/content/1/2/078
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
h
(AAV) as the gene transfer agent have also been reported
[14,15]. No significant side effects have been observed
and some evidence of correction of the chloride defect
has been suggested.
Liposome–plasmid complexes have been tested in several
clinical trials [16–21]. Of these, five were double-blind
placebo-controlled studies. Three trials with a similar
design showed a partial correction of the chloride trans-
port defect in the nose [16–18]. In a further study, com-
plexes were delivered to the lungs by nebulisation [20]
with an approximate 20% restoration of chloride transport
towards normal values. Administration was associated
with a transient febrile reaction that did not occur in the
control group, who received only the lipid; this reaction
might have been attributable to the bacterial origin of the
DNA [22]. None of these studies showed any correction
of the sodium defect, and vector-specific mRNA was only
inconsistently found.
A wealth of data have emerged from all of these studies,
reflecting enormous progress but also helping to focus on
the key difficulties. The principal issue is to improve the
efficiency of gene transfer, but questions relating to the
level of efficiency needed and the target cell population
also need addressing. The key problem of efficiency can
be considered in terms of either improving vectors or over-
coming biological barriers. An intrinsic function of the
lining epithelium of the airways is to prevent penetration by
foreign materials and invading organisms. Thus, a complex
series of epithelial barriers, including a mucous layer that
inhibits gene transfer [23], a glycocalyx, an apical cell
membrane and tight junctions between the cells, conspire
to keep out intraluminally delivered materials, including
both viral and non-viral vectors. This problem is com-
pounded in CF by the presence of thick, infected sputum,
also known to inhibit gene transfer [24], and plugging of
the small airways with mucus. The use of adjunctive
mucolytic agents or the abrogation of tight junction barrier
function either with detergents or with antibodies against
intrinsic tight junction components, are just two novel
strategies being investigated to overcome these barriers.
In addition, much effort is being devoted to the modifica-
tion of vectors. For adenovirus, AAV and other viruses, the
appropriate receptors are largely confined to the basolat-
eral cell membrane. Thus, attempts are now being made to
adapt viral entry by using apically sited receptors such as
the UTP-binding P2Y2 receptor. Novel viruses are
increasingly being investigated, and cationic liposomes
and polymers are increasingly being coupled to peptides,
sugars and viral particles to try to increase gene transfer
efficiency. The vexing question of how much effective
gene delivery and expression is required to achieve clinical
benefit remains unresolved, but the level is likely to be low.
If gene transfer is achieved in only a certain proportion of
cells within the airway epithelium, then studies suggest
that 6–10% of cells need to be corrected to reverse the
chloride defect and 100% for the sodium defect [25,26].
If, in contrast, delivery occurs to every cell, then levels of
approximately 5% of normal CFTR mRNA can correct the
chloride defect and reverse the intestinal pathology in CF
mice [27]. These goals have not yet been reached but the
relatively low levels that might be needed are encouraging.
CF affects the conducting airways rather than the alveoli.
These include both the larger bronchial regions lined by a
pseudostratified columnar epithelium and containing
numerous submucosal glands, and the small bronchiolar
regions lined by a simple columnar epithelium devoid of
glands. A central question for CF gene therapy is which
cell type and which region (large or small airways) to
target. Although ciliated superficial epithelium is abundant
and displays the ion transport defects in patients with CF,
the submucosal glands are the cells expressing the
highest CFTR levels in the lung and might well need to be
targeted for clinical benefit. This raises considerations of
delivery, because topical application is unlikely to reach
these cells. Further, most results suggest that small
airways are both the initial and the major site of disease in
CF. Again, the effective delivery of cDNA to these areas is
difficult with present nebuliser technology and remains an
important strategic issue.
A final important issue relates to repeated application. All
of the current vectors are likely to produce episomal gene
transfer, and the current duration of expression after a
single application is measurable in weeks. This does not
matter as long as multiple applications are feasible. In this
regard, cationic liposomes seem to have an important
advantage, with a third application having been shown to
be as effective as the first in a recent trial of multiple appli-
cations of liposome-mediated gene therapy to the nasal
epithelium of CF patients [28]. The repeated administra-
tion of viral vectors results in the production of neutralising
antibodies that limit reapplication efficiency, and consider-
able effort is being expended to reduce this problem.
Gene therapy will probably prove to be most beneficial if
given very early, before the onset of established infection
or inflammation in the lungs. Thus, questions about the
execution and design of trials in the paediatric population
are likely to become the focus of new efforts [29]. The rig-
orous measurement of gene transfer efficiency in vivo and
the development of markers – both real and surrogate – of
clinical benefit also remain important challenges.
In conclusion, CFTR gene therapy has proved to be safe
so far and has produced a proof of principle with respect
to CFTR function in the target organ in humans, an
encouraging position in a young field. Nevertheless, it is
not yet a clinically effective treatment for CF lung disease.Respiratory Research    Vol 1 No 2 Stern et al
The inevitable pessimism that follows unrealistic expecta-
tions of a rapid cure has dogged the recent media view of
gene therapy. Gene therapy is clearly at the typical stage
of new drug development where considerable and
unglamorous effort needs to be expended to move from
proof of principle to clinical product. Encouraging
progress in gene therapy can clearly be found both within
the CF field and in parallel areas. Thus, a clinical study of
intramuscular injection of an AAV vector expressing factor
IX in adults with severe haemophilia B [30] demonstrated
prolonged expression of the protein and positive changes
in clinical endpoints, including circulating levels of factor
IX and the frequency of infusion of factor IX protein. The
questions that remain to be answered for successful CF
gene therapy have now been clearly defined, and gene
therapy for CF remains the most promising possibility for
curative rather than symptomatic therapy.
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